All IndicationsInfectious DiseasePhase 3Phase 2Phase 2Phase 2Phase 2
🦠
Pneumococcal Vaccines
1
Companies
5
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
PCVX
Vaxcyte, Inc.
31 valent pneumococcal conjugate vaccine
PCVX
Vaxcyte, Inc.
0.5 ml dose of 1.1 mcg VAX-24
PCVX
Vaxcyte, Inc.
0.5 mL of the low dose VAX-31
PCVX
Vaxcyte, Inc.
24 valent pneumococcal conjugate vaccine
PCVX
Vaxcyte, Inc.
24-Valent Pneumococcal Conjugate Vaccine
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| PCVX Vaxcyte, Inc. | 31 valent pneumococcal conjugate vaccine | Phase 3 | — | — | — |
| PCVX Vaxcyte, Inc. | 0.5 ml dose of 1.1 mcg VAX-24 | Phase 2 | — | — | — |
| PCVX Vaxcyte, Inc. | 0.5 mL of the low dose VAX-31 | Phase 2 | — | — | — |
| PCVX Vaxcyte, Inc. | 24 valent pneumococcal conjugate vaccine | Phase 2 | — | — | — |
| PCVX Vaxcyte, Inc. | 24-Valent Pneumococcal Conjugate Vaccine | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
1
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.